Seelos_full logo and icon color.jpg
Seelos Therapeutics Announces Closing of Public Offering of Common Stock
February 13, 2020 16:30 ET | Seelos Therapeutics, Inc.
NEW YORK, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Announces Pricing of $5 Million Public Offering of Common Stock
February 10, 2020 20:00 ET | Seelos Therapeutics, Inc.
NEW YORK, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Announces Update to Parkinson’s Disease Program SLS-007
January 28, 2020 08:02 ET | Seelos Therapeutics, Inc.
Delivery of SLS-007 to Utilize an Adeno-Associated Virus (AAV) VectorSLS-007 to Become Seelos’ Second Gene Therapy Program Focused on Parkinson’s  NEW YORK, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Seelos...
Seelos_full logo and icon color.jpg
Seelos Therapeutics to Participate in Upcoming Investor Conferences in December
November 01, 2019 10:00 ET | Seelos Therapeutics, Inc.
NEW YORK, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it will participate in the Evercore ISI 2nd...
Seelos_full logo and icon color.jpg
Seelos Therapeutics to Participate in Upcoming Investor Conference in November
October 18, 2019 09:00 ET | Seelos Therapeutics, Inc.
NEW YORK, Oct. 18, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it will participate in the Jefferies 2019...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Announces the Addition of Scott Applebaum as Lead Strategic Regulatory Consultant
October 15, 2019 09:00 ET | Seelos Therapeutics, Inc.
NEW YORK, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, today announced the addition of Scott Applebaum to its team as lead...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Announces Pricing of $6.7 Million Registered Direct Offering
August 23, 2019 09:00 ET | Seelos Therapeutics, Inc.
NEW YORK, Aug. 23, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it has entered into a securities purchase...
Seelos_full logo and icon color.jpg
Seelos Therapeutics to Ring Opening Bell at Nasdaq on August 12th
August 06, 2019 09:00 ET | Seelos Therapeutics, Inc.
NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that Raj Mehra, PhD, Chairman, Founder, and CEO of...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Reports Q2 2019 Pipeline Update
August 01, 2019 09:00 ET | Seelos Therapeutics, Inc.
NEW YORK, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, today released its second quarter pipeline update. “We have made...